Research programme: respiratory disease therapy - Aus BioAlternative Names: MD 990
Latest Information Update: 19 Apr 2010
At a glance
- Originator Aus Bio Limited
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Respiratory tract disorders
Most Recent Events
- 19 Apr 2010 Preclinical development is ongoing Australia
- 12 May 2005 Preclinical trials in Respiratory tract disorders in Australia (unspecified route)